Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology research at its South San Francisco, California, and Westborough, Massachusetts, sites.
In this bonus episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel take a look at Q1 job market performance and what it signals for the coming months.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.
Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.
Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the biotech is developing both as an injectable and as a pill.
Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the federal government’s public repository for studies, according to internal data from the FDA.
Bringing patients into the drug development process early has proven to save time, money and resources.
PRESS RELEASES
Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) Testing
Further advancements in Europe and the US increase capacity and process efficiency ● Construction of new clinical manufacturing facility in Des Plaines on schedule ● Established Skokie site with ongoing strong performance for biotech partners ● Infrastructure upgrades at Austrian site further streamline customers’ path to clinic